Human Longevity

Sun Genomics is a precision nutrition company focused on curing dysbiosis through the gut microflora and personalized solutions. Its flagship product Floré, is a microbiome test and custom synbiotics solution that utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a completely personalized product based on their unique gut profiles. The company also offers: Floré Tots, Kids, and Baby, available for kids up to age 0-12, and comes in an easy digestive powder to mix with their favorite drink. Floré Clinical, which is specifically for professional practitioners and their patients. Floré Defense, Balance, and Performance for sports teams and athletes.

Solius is a new technology to help vitamin D deficient Canadian for human health. The company is designed to harness the healing powers of the sun to stimulate the production of vitamin D without the harmful UVA rays or issues related to supplements. They provide the benefits of the sun without the harmful rays to unlock the healing powers of the human body, improving physical, mental, and immune function. Solius stimulates the body’s production of hormones and peptides critical to many aspects of health and wellbeing. Every element of SOLIUS has been designed to enhance the user experience and set a new standard for medical devices everywhere. Solius also developed an ultraviolet light system to help treat COVID-19. Solius was founded in 2011 and is headquartered in Bainbridge Island, Washington, United States.

DoctorsForMe.AI helps patients with complex conditions find the doctors that they need the most. When you or your family is diagnosed with a cancer or other complex condition, one of the important decisions is to find the right doctors. We measure a doctor's expertise and clinical excellence by analyzing billions of data points about doctors worldwide. Our goal is to precisely and independently identify the right doctors that treat your conditions the best.

Celularity is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious and degenerative diseases. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.

OxStem plans to develop small molecule drugs that can activate repair mechanisms that already exist within the body. Building on decades of experience in medicinal chemistry, OxStem will design drugs that can programme resident stem and stem-like cells in situ to treat currently untreatable age-related conditions.

Cypher Genomics is a genome informatics company that develops and delivers automated human genome interpretation software solutions for clinical labs, pharmaceutical companies, and population genomics efforts. Their automated genomic interpretation platform allows clinical laboratories to tune Cypher Genomics' sensitivity and specificity profiles to develop molecular tests for diagnostic and prognostic use and pharmaceutical companies to discover biomarkers from whole genome sequence data in sample sizes typical of early stage drug development studies. Cypher Genomics was founded by Ashley Van Zeeland in 2011 and is headquartered in La Jolla, California. It is now acquired by Human Longevity.